China News Service, June 19 (Reporter Chen Jing) The reporter was informed on the 19th that Fengxian District, one of the five major new cities under construction in Shanghai, is actively building a platform to promote Dongfang Meigu to become a China Biomedical CDMO (Contract R&D and Production Organization) The new heights where "industry, capital, talents, and innovation are the most concentrated".
It is reported that the pharmaceutical CDMO is customized R&D and production in the field of medicine, which is an emerging R&D and production outsourcing model.
In recent years, the global pharmaceutical CDMO industry has maintained rapid development, and China's performance has been particularly prominent.
Oriental Beauty Valley is a cluster of beauty and health industries in Shanghai. At present, more than 200 biomedical companies have gathered. In 2020, the output value of biomedical regulations will account for 13% of Shanghai's total.
Fengxian District is currently one of the few areas in Shanghai where a full range of drugs can be produced.
On the same day, the "Oriental Beauty Valley Life and Health Integration Development Zone" launched a new round of global investment in biomedical characteristic space carriers. 13 carriers were launched and a total of 1.16 million square meters of properties were launched.
According to reports, the "Oriental Beauty Valley Life and Health Integration Development Zone" is one of the first batch of five biomedical characteristic industrial parks issued by Shanghai in 2020, and is included in the Shanghai Biomedical Industrial Park Development Action Plan.
At the "2021 Oriental Beauty Valley Life and Health Development Forum and Shanghai CDMO Industry Investment Development Conference" held on the same day, the reporter learned that with the continuous expansion of the pharmaceutical market, the continuous upgrading of pharmaceutical innovation and the accelerated transfer of overseas production capacity, China’s biomedical CDMO industry It will usher in a period of prosperity.
According to reports, in terms of biomedical CDMO, many well-known companies have settled in Fengxian, and the biomedical industry is full of vitality.
Yuan Quan, deputy secretary and acting mayor of the Fengxian District Committee of the Communist Party of China in Shanghai, revealed that in the next three years, the district will launch 6000 acres of land and 4 million square meters of properties for the biopharmaceutical industry. There is no shortage of space".
On the same day, "CANNOVA Oriental Beauty Valley Life and Health Industrial Park", "Organoid Platform of School of Life Sciences of Fudan University" and "Alumni Entrepreneurship Center of School of Life Sciences of Fudan University" were inaugurated one after another, which marked Fengxian District's biomedical industry innovation ability to a higher level.
Prior to this, Fengxian District has gathered 102 biomedical companies that have been approved as high-tech enterprises, 18 municipal science and technology giants (including cultivation), 2 national-level enterprise technology centers, and 2 national-level incubators.
In recent years, WuXi Biologics’ "Global Innovative Biopharmaceutical R&D and Pharmaceutical Integration Center", Pasteur Institute’s "Infectious Disease Immunity Diagnosis and Treatment Technology Collaborative Innovation Platform", and Yikang Medical’s "Non-invasive and Intelligent Innovation Platform for Genetic Testing" have accelerated the introduction.
On the same day, the 10 billion life and health fund jointly settled in Oriental Beauty Valley, and the six representatives of SIIC Capital, China Finance China Investment, ICBC Capital, Shanghai Science and Technology Venture Capital, Furong Investment, and Yida Capital jointly opened the prelude to Fengxian Biomedicine Investment. Inject financial impetus into the development of biomedicine.
Fengxian District Party Secretary Zhuang Mudi said that the biomedical CDMO industry plays a key role in the link between manufacturing and new drug research and development. It is a lubricant for the prosperity of the industrial ecology and a catalyst for industrial transformation and upgrading.
Fengxian will take the biomedical CDMO industry as an important starting point for the high-quality development of "Oriental Beauty Valley" and make "Oriental Beauty Valley" the core of scientific research and development.
The secretary of the district party committee stated that Fengxian will target the innovative highland of the biomedical industry with international influence, continue to build a circle of high-quality friends, provide a hard environment for development, accelerate the formulation of highly penetrating policies, and change "nanny-style" services to " "Mother-like" service allows more leading companies and industry elites to come from far away, to jointly promote the cultivation of pharmaceutical innovation industry chains and ecosystems, and guide high-quality resources to gather, communicate and integrate in Fengxian.
The "2021 Oriental Beauty Valley Life and Health Development Forum and Shanghai CDMO Industry Investment Development Conference" held on the same day was hosted by the Shanghai Municipal Biomedical Industry Development Leading Group Office and the People's Government of Fengxian District, Shanghai.
Speech by Cai Wei, Vice Chairman of the Central Committee of the Peasants and Workers Party, Chairman of the Shanghai Municipal Committee of the Peasants and Workers Party, and Deputy Director of the Shanghai Municipal People's Congress; Zhuang Mudi, Secretary of the Fengxian District Committee of the Communist Party of China in Shanghai; Jin Li, Academician of the Chinese Academy of Sciences, Executive Vice President of Fudan University, and Dean of Shanghai Medical College of Fudan University In his speech, Liu Ping, deputy director of the Shanghai Municipal Commission of Economy and Information Technology, interpreted the Shanghai biomedical industry policy.
Zhang Ying, chairman of the Shanghai Economic and Informatization Commission of the Peasants and Workers Party, deputy director of the Shanghai Economic and Informatization Commission, Zhu Qigao, deputy director of the Shanghai Science and Technology Commission, and Bao Beiying, member of the Standing Committee of the Shanghai Fengxian District Committee and Minister of the United Front Work Department, attended the meeting. .
The meeting was presided over by Gu Tong, deputy head of the Fengxian District Government of Shanghai.